Literature DB >> 22959617

Ficolins in complement activation.

Misao Matsushita1.   

Abstract

Ficolins are a group of multimeric lectins made up of single subunits each of which is composed of a collagen-like domain and a fibrinogen-like domain. Most of the ficolins identified to date bind to acetylated compounds such as N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc). Ficolins in serum are complexed with MBL-associated serine proteases (MASPs) and their truncated proteins. These lectins play an important role in innate immunity. Binding of the ficolin-MASP complex to carbohydrates present on the surface of microbes initiates complement activation via the lectin pathway.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959617     DOI: 10.1016/j.molimm.2012.08.017

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  21 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

2.  Pattern Recognition Molecules of the Lectin Pathway-Screening of Patients with Suspected Immunodeficiency.

Authors:  Clara Mistegård Jørgensen; Lisbeth Jensen; Mette Christiansen; Mette Bjerre; Jens Magnus Bernth Jensen; Steffen Thiel
Journal:  J Clin Immunol       Date:  2019-08-03       Impact factor: 8.317

3.  Serum opsonin ficolin-A enhances host-fungal interactions and modulates cytokine expression from human monocyte-derived macrophages and neutrophils following Aspergillus fumigatus challenge.

Authors:  Stefan Bidula; Darren W Sexton; Silke Schelenz
Journal:  Med Microbiol Immunol       Date:  2015-09-04       Impact factor: 3.402

4.  Association of Ficolin-2 Serum Levels and FCN2 Genetic Variants with Indian Visceral Leishmaniasis.

Authors:  Anshuman Mishra; Justin S Antony; Pandarisamy Sundaravadivel; Hoang Van Tong; Christian G Meyer; Reshma D Jalli; Thirumalaisamy P Velavan; Kumarasamy Thangaraj
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

5.  Peptide Inhibitor of Complement C1 (PIC1) Rapidly Inhibits Complement Activation after Intravascular Injection in Rats.

Authors:  Julia A Sharp; Pamela S Hair; Haree K Pallera; Parvathi S Kumar; Clifford T Mauriello; Julius O Nyalwidhe; Cody A Phelps; Dalnam Park; Nicole M Thielens; Stephen M Pascal; Waldon Chen; Diane M Duffy; Frank A Lattanzio; Kenji M Cunnion; Neel K Krishna
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

6.  A novel IgM-H-ficolin complement pathway to attack allogenic cancer cells in vitro.

Authors:  Xiaoying Lei; Chaoxu Liu; Kazem Azadzoi; Cuiling Li; Fan Lu; An Xiang; Jianbin Sun; Yanhai Guo; Qingchuan Zhao; Zhen Yan; Jinghua Yang
Journal:  Sci Rep       Date:  2015-01-16       Impact factor: 4.379

Review 7.  The lectin pathway of complement and rheumatic heart disease.

Authors:  Marcia Holsbach Beltrame; Sandra Jeremias Catarino; Isabela Goeldner; Angelica Beate Winter Boldt; Iara José de Messias-Reason
Journal:  Front Pediatr       Date:  2015-01-21       Impact factor: 3.418

8.  A New Ligand-Based Method for Purifying Active Human Plasma-Derived Ficolin-3 Complexes Supports the Phenomenon of Crosstalk between Pattern-Recognition Molecules and Immunoglobulins.

Authors:  Aleksandra Man-Kupisinska; Mateusz Michalski; Anna Maciejewska; Anna S Swierzko; Maciej Cedzynski; Czeslaw Lugowski; Jolanta Lukasiewicz
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

Review 9.  Complement, c1q, and c1q-related molecules regulate macrophage polarization.

Authors:  Suzanne S Bohlson; Sean D O'Conner; Holly Jo Hulsebus; Minh-Minh Ho; Deborah A Fraser
Journal:  Front Immunol       Date:  2014-08-21       Impact factor: 7.561

Review 10.  Neutrophil-Mediated Phagocytosis of Staphylococcus aureus.

Authors:  Kok P M van Kessel; Jovanka Bestebroer; Jos A G van Strijp
Journal:  Front Immunol       Date:  2014-09-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.